Pharmaceutical companies are facing the prospect of sickly returns, increasing development costs and patent expiries. This has prompted them to turn to resources outside their own research and development capabilities, writes Nicola Boyes.
Amendments Set to Clear Ambiguity The US government is imposing transparency rules on the relationship between physicians and pharmaceutical companies.
Indian Takeover Targets As the Indian drug market is set for major growth, foreign investors are finding the country's companies appealing.